Mental Health and Aging: The Role of Primary Care in Overcoming Barriers to Treatment
Physical and mental health are inextricably intertwined — senior-focused primary care can help bridge the treatment gap
Depression Trial Win Moves Intra-Cellular Drug Closer to Label Expansion & Blockbuster Status
Intra-Cellular Therapies reported its drug Caplyta met the main and secondary goals in the first of three pivotal studies in major depressive disorder. Success in two of them could support expanding the label of the drug, which is currently approved in schizophrenia and bipolar depression.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
PureTech Startup Gets $100M to Try For Success Where Sage & Others Fall Short in Depression
Seaport Therapeutics’ drug candidates are delivered through the lymphatic system, an approach that could overcome some limitations of neuropsychiatric medicines, including products from Sage Therapeutics. The startup stems from the research of PureTech Health.
Neuro Biotech Alto Adds $128M in IPO Cash for Biomarker-Based Psych Drugs
Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company's two most advanced programs are depression drugs in mid-stage development.
Digital Health App Helps Asthma and Depression, 2 Trials Find
An AI-driven app called juli improved symptoms of asthma and depression, two randomized controlled trials found. The app takes in data from electronic medical records, smartphones, wearable devices, the environment and patient questionnaires to provide personalized health recommendations.
Evernorth: More Women Experienced Post-Miscarriage Depression During Pandemic
Just 10% of women who had post-miscarriage depression during the pandemic received the “full spectrum of treatment” through therapy and antidepressants, according to a new report by Evernorth Research Institute.
At ViVE 2024, Panelists Share Prior Authorization Progress and Frustration in Payer Insights Program
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
Inside One Startup’s Effort to Make Mental Healthcare Progress Seem Less Subjective
Less than 20% of behavioral healthcare providers collect data on how patients are progressing with their treatment. To buck this trend, Two Chairs is rolling out “mental health snapshots,” which are consistent summaries of patients’ well-being designed to offer real-time insight to both clinicians and clients.
For Neuro Biotech Lusaris, Depression Therapy Starts by Lifting the Tongue
Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.
‘Paradoxical’ placebo response spells Phase 3 failure for Relmada depression drug
A Relmada Therapeutics drug candidate for major depressive disorder failed a Phase 3 clinical trial, but the biotech isn’t giving up on its pill yet. It’s pinning its hopes on additional studies testing the therapy as an additional treatment alongside other depression drugs.
Chronic loneliness is killing people: The solution is personal
In order to make an impact and improve physical and mental health, we need to recognize the need to approach loneliness as a condition. Building connections through social intervention is the most direct way to affect change.
Unlocking Transparency in PBM Pricing
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Better late than never? Axsome depression drug is approved a year after FDA delay
The FDA has approved Axsome Therapeutics drug Auvelity as a treatment for major depressive disorder in adults. The regulatory decision makes the twice-daily pill the first new oral drug approved to address a novel depression target in more than 60 years.
The role of mindfulness in healthcare from behavioral health to physical therapy
Clinicians used to wonder if there was a role for mindfulness meditation in healthcare. But after the Covid-19 pandemic laid bare the overwhelming need for practical solutions in behavioral health, the question has shifted to what role it can play.
Psychedelic biotech Eleusis enters SPAC deal to take depression drug to the clinic
Eleusis is developing a formulation of the psychedelic compound psilocybin that overcomes limitations of pill versions of the drug. Depression is Eleusis’s lead disease target but the biotech notes that its research has shown the potential to bring psychedelic drugs beyond psychiatry.
Health plans can help combat the epidemic of loneliness for older Americans
Centers for Medicare & Medicaid Services only recently gave the green light for Medicare Advantage (MA) plans to provide a wider range of benefits that address social determinants of health. With that new charge, it’s time for health care payers to join the fight against loneliness.
Smartphones could be used to detect depression, Verily finds
A study published by Verily researchers showed that some smartphone metrics, such as sentiment in weekly voice diaries, matched up with the severity of users’ depression as determined by PHQ-9 scores. Even if these technologies could be used to track mental health, it’s not clear how they will fit into physician workflows or how comfortable people will be using their smartphones in this way.